SYDNEY, Australia, Dec. 14 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of Pulmocor SA to market and distribute its asthma diagnostic tool, Aridol in Portugal.
"Portugal was one of the 13 European countries included in the successful mutual recognition procedure earlier this year," said Pharmaxis Chief Executive Officer Dr Alan Robertson.
"Bronchial challenge testing is a common procedure in Potuguese hospitals and we have sought a distributor that already has a strong franchise in this market and will provide the best support for Aridol; we are delighted to announce our agreement with Pulmocor."
Mr Ricardo Villar, President of Pulmocor said, "Founded in 1982, Pulmocor has a strong reputation for quality and excellence among respiratory specialists and brings many years of bronchial challenge testing experience to the promotion of Aridol. Pulmocor is currently extending its activity into specialist pharmaceutical products and Aridol represents an important addition to our portfolio and our ability to service respiratory specialists."
Aridol has already been approved in Europe by the mutual recognition procedure and is now awaiting confirmation of national approval in Portugal.
A simple to use airways inflammation test, Aridol is administered as a dry powder in a hand held inhaler. Doctors can use the results of this test to identify airway hyper-responsiveness -- a hallmark of asthma.
To find out more about Pharmaxis go to http://www.pharmaxis.com.au .
To find out more about Aridol go to http://www.pharmaxis.com.au/target-diseases-and-products/our-products/our-products_home.cfm .
(Note: If the URL above wraps to a second line, paste both lines into the browser.)
Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
CONTACT:
Alan Robertson - Chief Executive Officer
Tel: +61-2-9454-7200
Email: alan.robertson@pharmaxis.com.au
Released through:
United States:
Brandon Lewis, Trout Group
Tel: +1-646-378-2915
Email: blewis@troutgroup.com
Australia:
Felicity Moffatt
Tel: +61-418-677-701
Email: moffattf@healthpr.com
